Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis

Stroke

Volumn 41, Issue 4, 2010, Pages 674-679

  Hoke, Matthias ^a   Amighi, Jasmin ^a   Mlekusch, Wolfgang ^a   Schlager, Oliver ^a   Exner, Markus ^b   Sabeti, Schila ^a   Dick, Petra ^a   Koppensteiner, Renate ^a   Minar, Erich ^a   Rumpold, Helmut ^b   Wagner, Oswald ^b   Schillinger, Martin ^a  

^a Division of Angiology   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Carotid atherosclerosis; Cystatin C; Major adverse cardiovascularevents; Renal dysfunction

Indexed keywords

CREATININE; CYSTATIN C;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STROKE; ULTRASOUND;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CREATININE; CYSTATIN C; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 77950254560     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.573162     Document Type: Article

References (19)

1. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121-1129.
2. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002;61:1486-1494.
3. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997;28:557-563.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
5. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141: 929-937.
6. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, Vera M, Piera C, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29-34.
7. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221-226.
8. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115:173-179.
9. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352: 2049-2060.
10. de Boer IH, Katz R, Cao JJ, Fried LF, Kestenbaum B, Mukamal K, Rifkin DE, Sarnak MJ, Shlipak MG, Siscovick DS. Cystatin C, albuminuria, and mortality among older adults with diabetes mellitus. Diabetes Care. 2009;32:1833-1838.
11. Schillinger M, Exner M, Mlekusch W, Sabeti S, Amighi J, Rumpold H, Maurer G, Wagner O, Minar E. Inflammation and Carotid Artery Risk for Atherosclerosis Study (ICARAS). Circulation. 2005;111:2203-2209.
12. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II system. Scand J Clin Lab Invest. 1999;59:1-8.
13. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/Am College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol. 2000;36:959-969.
14. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
15. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103: 1721-1726.
16. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85-97.
17. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. The relationship between non-traditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis. 2008;51:212-223.
18. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B. Serum albumin, C-reactive protein, inter-leukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006; 47:139-148.
19. Spence JD, Tamayo A, Lownie SP, Ng WP, Ferguson GG. Absence of microemboli on transcranial Doppler identifies low-risk patients with asymptomatic carotid stenosis. Stroke. 2005;36:2373-2378.